1 |
LAM A K Y. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours[J]. Endocr Pathol, 2017, 28(3): 213-227.
|
2 |
MOON J K, MATTEI P. Pheochromocytoma and paraganglioma[J]. Semin Pediatr Surg, 2020, 29(3): 150926.
|
3 |
NEUMANN H P H, YOUNG W F, ENG C. Pheochromocytoma and paraganglioma[J]. N Engl J Med, 2019, 381(6): 552-565.
|
4 |
PACAK K, TAÏEB D. Pheochromocytoma (PHEO) and paraganglioma (PGL)[J]. Cancers, 2019, 11(9): 1391.
|
5 |
LENDERS J W, DUH Q Y, EISENHOFER G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014, 99(6): 1915-1942.
|
6 |
LENDERS J W M, EISENHOFER G. Update on modern management of pheochromocytoma and paraganglioma[J]. Endocrinol Metab Seoul Korea, 2017, 32(2): 152-161.
|
7 |
TURCHINI J, CHEUNG V K Y, TISCHLER A S, et al. Pathology and genetics of phaeochromocytoma and paraganglioma[J]. Histopathology,2018,72(1): 97-105.
|
8 |
DAHIA P L. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity[J]. Nat Rev Cancer, 2014, 14(2): 108-119.
|
9 |
KAVINGA GUNAWARDANE P T, GROSSMAN A. The clinical genetics of phaeochromocytoma and paraganglioma[J].Arch Endocrinol Metab,2017,61(5): 490-500.
|
10 |
ROSALES-CASTILLO A, BUSTOS-MERLO A, PADILLA L G. Hereditary multiple paraganglioma[J]. Med Clin, 2021, 157(9): 455-456.
|
11 |
JOCHMANOVA I, ABCEDE A M T, GUERRERO R J S, et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents[J]. J Cancer Res Clin Oncol, 2020, 146(4): 1051-1063.
|
12 |
KING K S, PRODANOV T, KANTOROVICH V, et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations[J]. J Clin Oncol, 2011, 29(31): 4137-4142.
|
13 |
NEUMANN H P H, YOUNG W F, ENG C. Pheochromocytoma and paraganglioma[J]. N Engl J Med, 2019, 381(6): 552-565.
|
14 |
FANG F, DING L, HE Q,et al.Preoperative management of pheochromocytoma and paraganglioma[J]. Front Endocrinol (Lausanne), 2020, 11: 586795.
|
15 |
JOCHMANOVA I, WOLF K I, KING K S, et al. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations[J]. J Cancer Res Clin Oncol, 2017, 143(8): 1421-1435.
|
16 |
TUFTON N, SAHDEV A, AKKER S A. Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers[J]. J Endocr Soc, 2017, 1(7): 897-907.
|
17 |
JAIN A, BARACCO R, KAPUR G. Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management[J]. Pediatr Nephrol, 2020, 35(4): 581-594.
|
18 |
TANABE A, NARUSE M, NOMURA K, et al. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma[J]. Horm Cancer, 2013, 4(2): 103-110.
|
19 |
JAWED I, VELARDE M, DÄRR R, et al. Continued tumor reduction of metastatic pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy[J]. Cell Mol Neurobiol, 2018, 38(5): 1099-1106.
|
20 |
NOMURA K, KIMURA H, SHIMIZU S, et al. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy[J].J Clin Endocrinol Metab,2009,94(8):2850-2856.
|
21 |
FUJIWARA Y, OHMOTO A, FUKUDA N, et al. Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy[J]. Endocr J, 2021, 68(6): 671-681.
|
22 |
VOGEL J, ATANACIO A S, PRODANOV T, et al. External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma[J]. Front Oncol, 2014, 4: 166.
|
23 |
JASIM S, JIMENEZ C. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(2): 101354.
|
24 |
JOCHMANOVA I, PACAK K. Genomic landscape of pheochromocytoma and paraganglioma[J]. Trends Cancer, 2018, 4(1): 6-9.
|
25 |
GONCALVES J, LUSSEY-LEPOUTRE C, FAVIER J, et al. Emerging molecular markers of metastatic pheochromocytomas and paragangliomas[J]. Ann Endocinol(Paris), 2019, 80(3): 159-162.
|
26 |
SARKADI B, MESZAROS K, KRENCZ I, et al. Glutaminases as a novel target for SDHB-associated pheochromocytomas/paragangliomas[J]. Cancers, 2020, 12(3): 599.
|
27 |
RAI S K, BRIL F, HATCH H M, et al. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors[J]. Metabolism, 2020, 110: 154297.
|
28 |
CASSOL C A, WINER D, LIU W, et al. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas[J]. Mod Pathol, 2014, 27(8): 1050-1062.
|